Sana Biotechnology, Inc. — Form 10-Q
Filed August 10, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 18/100
What the filing says
Sana Biotechnology entered into a Second Amendment with The Regents of the University of California (effective May 1, 2026) to update the Due Diligence section of their original exclusive licensing agreement. Sana must pay an unspecified amendment fee (amount redacted as [***]) to UC within a redacted timeframe; the fee is non-refundable and non-creditable against future royalties. All other terms of the original 2019 agreement remain in effect.
Why this rating
Amendment to existing academic license with routine updating of terms; redacted fee amount prevents materiality assessment but likely modest relative to $295M market cap. Standard contract housekeeping, not a new commercial event.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.